Form 8K Repligen Corporation For: 30 October
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Repligen Corporation (RGEN)
Track the Repligen share price today and view real-time RGEN share price data, including charts, technicals, and key financials. View the RGEN premarket stock price ahead of the market session or assess the after hours quote. Explore RGEN stock price movements, trading volume, and market activity across the NASDAQ exchange.
What Is the Repligen Stock Price Today?
The Repligen stock price today is 176.94.
What Is the Stock Symbol for Repligen?
The stock symbol for Repligen is ""RGEN.""
What Stock Exchange Does Repligen Trade On?
Repligen is listed and trades on the NASDAQ stock exchange.
Is Repligen a Good Stock to Buy?
Determining whether Repligen or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RGEN quote. (ISIN: US7599161095)
What Is the Repligen Stock Price Today?
The Repligen stock price today is 176.94.
What Is the Stock Symbol for Repligen?
The stock symbol for Repligen is ""RGEN.""
What Stock Exchange Does Repligen Trade On?
Repligen is listed and trades on the NASDAQ stock exchange.
Is Repligen a Good Stock to Buy?
Determining whether Repligen or any stock is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the RGEN quote. (ISIN: US7599161095)
Currency in USD
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
171.23
180.45
52 wk Range
100.99
198.87
RGEN is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
171.23180.45
52 wk Range
100.99198.87
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
RGEN Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Neutral
Price Target
202.22
Upside
+14.29%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
15 analysts have revised their earnings downwards for the upcoming period
- Form 8K Repligen Corporation For: 30 October
- Investing.com
Repligen Corp receives Investment Bank Analyst Rating Update- Investing.com
Pro
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Analyst Ratings
17 Buy
4 Hold
0 Sell
Ratings:
21 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 202.22
(+14.29% Upside)
Repligen Corporation SWOT Analysis
Bioprocessing Pionee | Repligen leads the $12B bioprocessing market with innovative technologies, strategic acquisitions, and a focus on new modalities driving growth |
Financial Resilience | Despite market challenges, Repligen maintains strong financials with a 51.15% gross profit margin and upward revenue guidance for 2025 |
Market Dominance | Explore Repligen's unique position, with 80% of its portfolio facing little to no competition, fostering pricing power and market leadership |
Future Trajectory | Analyst targets range from $150 to $220, reflecting varied views on Repligen's growth potential amid industry recovery and expansion |
Repligen Corporation Earnings Call Summary for Q3/2026
- Repligen posted Q3 2026 revenue of $209M (up 11% YoY) and adjusted EPS of $0.53, beating estimates of $206.7M and $0.46 per share respectively.
- Organic revenue growth hit record 12.5%; Chromatography rose 50%+, Proteins 40%+, Analytics 20%, while Filtration declined 11% amid customer headwinds.
- Company raised FY2026 guidance to $844M-$852M revenue with 12-13% organic growth; expects to exceed $1B revenue in 2027 for the first time.
- BioLife acquisition closed in October, expected to add $24M in 2026 revenue and be at least $0.05 accretive to 2027 earnings with integration underway.
- Shares fell 2.25% to $176.12 despite earnings beat as investors weighed timing delays in equipment revenue and near-term filtration weakness against outlook.
Last Updated: 28/10/2026, 12:14 am
Read Full TranscriptEarnings
Latest Release
27/10/2026
EPS / Forecast
0.53 / 0.46
Revenue / Forecast
209M / 206.7M
Compare RGEN to Peers and Sector
Metrics to compare | RGEN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipRGENPeersSector | |
|---|---|---|---|---|
P/E Ratio | −849.8x | −0.8x | −0.3x | |
PEG Ratio | 0.92 | 0.03 | 0.00 | |
Price/Book | 4.8x | 4.1x | 2.6x | |
Price / LTM Sales | 12.5x | 3.9x | 2.8x | |
Upside (Analyst Target) | 14.3% | 15.9% | 66.6% | |
Fair Value Upside | Unlock | −0.1% | 9.1% | Unlock |
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company’s products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System. It offers Protien A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification and quality control of biological drugs, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems. The company offers its products under the OPUS, XCell, XCell ATF, TFDF, KrosFlo, SIUS, ProConnex, Spectra/Por, NGL-Impact, SoloVPE, FlowVPE, RPM, XO, Metenova MixOne, and AVIPure and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
Ownership
Ownership Overview
Top Holders
People Also Watch
FAQ
What Is the Repligen (RGEN) Stock Price Today?
The Repligen stock price today is 176.94 USD.
What Stock Exchange Does Repligen Trade On?
Repligen is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Repligen?
The stock symbol for Repligen is "RGEN."
What Is the Repligen Market Cap?
As of today, Repligen market cap is 10.69B USD.
What Is Repligen's Earnings Per Share (TTM)?
The Repligen EPS (TTM) is -0.21.
When Is the Next Repligen Earnings Date?
Repligen will release its next earnings report on 24/02/2027.
From a Technical Analysis Perspective, Is RGEN a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Neutral.
How Many Times Has Repligen Stock Split?
Repligen has split 0 times.
How Many Employees Does Repligen Have?
Repligen has 2000 employees.
What is the current trading status of Repligen (RGEN)?
As of 31/10/2026, Repligen (RGEN) is trading at a price of 176.94 USD, with a previous close of 188.64 USD. The stock has fluctuated within a day range of 171.23 USD to 180.45 USD, while its 52-week range spans from 100.99 USD to 198.87 USD.
What Is Repligen (RGEN) Price Target According to Analysts?
The average 12-month price target for Repligen is 202.22 USD, with a high estimate of 235 USD and a low estimate of 175 USD. 17 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +14.29% Upside potential.
What Is the RGEN Premarket Price?
RGEN's last pre-market stock price is 176.32 USD. The pre-market share volume is 802,270.00, and the stock has decreased by -12.32, or -6.53%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.